Immuneering Corporation
Immuneering develops Deep Cyclic Inhibitors for oncology, including atebimetinib, a MEK inhibitor in late-stage clinical development for RAS/RAF/MAPK-driven cancers.
8-KNov 9Latest SEC filing
Nov 9Latest story
Immuneering develops Deep Cyclic Inhibitors for oncology, including atebimetinib, a MEK inhibitor in late-stage clinical development for RAS/RAF/MAPK-driven cancers.